295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
Growth of digital healthcare stabilised in 2023 The growth in the use of digital healthcare tools by care providers stabilised in 2023. This was mainly because most care providers were already using particular digital tools in 2022, such as the patient portal – on which patients can view the outcomes of examinations – and e-consultations (digital written contact with doctors).
Number of tuberculosis patients in the Netherlands increased in 2023 compared to 2022 In 2023, 710 people in the Netherlands were diagnosed with tuberculosis (TB). This was 12 per cent more than in 2022, when there were 634. In 2023, 471 patients had pulmonary TB. Of these 417 patients, 213 had open TB – the most contagious type.
Nitrogen and nature approach shows progress towards 2030, but targets are out of reach The nitrogen and nature measures that the government has implemented since 2021 are expected to make a positive contribution to the future quality of nature. The average exceedance of the critical loads for nitrogen deposition will decrease by a third up to 2030.
RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
Natura 2000 sites: nitrogen deposition on the decline, but still too high for much of nature The amount of nitrogen deposited on nature reserves that are vulnerable to this is falling. However, this decline is not sufficient to meet the targets the Dutch government has set itself. This is the conclusion of the RIVM monitoring report ‘Nitrogen deposition in Natura 2000 areas 2023’.
Breast implants can cause health problems even five years or more after placement Over the past 5 years, the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI) has received 977 reports of health problems related to breast implants. An analysis by RIVM has shown that 39% of the reported health problems started 5 or more years after the implant’s placement.
No indication that investigated mesh implants used to treat pelvic organ prolapse are unsafe RIVM has conducted a laboratory study into six mesh implants from different manufacturers used in the Netherlands in 2018. The study revealed no indication that these products are unsafe for patients.
Number of tuberculosis patients in the Netherlands decreased slightly in 2022 compared to 2021 The number of people with tuberculosis (TB) in the Netherlands decreased slightly in 2022. In 2022, there were 635 TB patients in the Netherlands. This is six per cent fewer than in 2021, when there were 673 patients.
Annual report ‘Tuberculosis in the Netherlands’ for 2021: slight increase in number of TB patients In 2021, the number of tuberculosis (TB) patients in the Netherlands rose slightly compared to the preceding year: up to 680 TB patients from 622 in 2020. However, the 2021 number was lower than the number for 2019 (754 patients).